Norma Adán

Norma Adán

Auto-generated profile, based on publicly available information

Norma Adán

Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Campus UNAM-Juriquilla, 76230 Querétaro, Mexico

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NANorma Adán
Norma Adán
JGJessica Guzmán-Morales
Jessica Guzmán-Morales
MLMaria G. Ledesma-Colunga
Maria G. Ledesma-Colunga
SPSonia I. Perales-Canales
Sonia I. Perales-Canales
AQAndrés Quintanar-Stephano
Andrés Quintanar-Stephano
CCCarmen Clapp
Carmen Clapp
Chondrocytes are the only cells in cartilage, and their death by apoptosis contributes to cartilage loss in inflammatory joint diseases, such as rheumatoid arthritis (RA). A putative therapeutic intervention for RA is the inhibition of apoptosis-mediated cartilage degradation. The hormone prolactin (PRL) frequently increases in the circulation of patients with RA, but the role of hyperprolactinemia in disease activity is unclear. Here, we demonstrate that PRL inhibits the apoptosis of cultured chondrocytes in response to a mixture of proinflammatory cytokines (TNF-α, IL-1β, and IFN-γ) by preventing the induction of p53 and decreasing the BAX/BCL-2 ratio through a NO-independent, JAK2/STAT3–dependent pathway. Local treatment with PRL or increasing PRL circulating levels also prevented chondrocyte apoptosis evoked by injecting cytokines into the knee joints of rats, whereas the proapoptotic effect of cytokines was enhanced in PRL receptor–null (Prlr–/–) mice. Moreover, eliciting hyperprolactinemia in rats before or after inducing the adjuvant model of inflammatory arthritis reduced chondrocyte apoptosis, proinflammatory cytokine expression, pannus formation, bone erosion, joint swelling, and pain. These results reveal the protective effect of PRL against inflammation-induced chondrocyte apoptosis and the therapeutic potential of hyperprolactinemia to reduce permanent joint damage and inflammation in RA.

1 February 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PPPablo Peñalver
Pablo Peñalver
EBEfres Belmonte-Reche
Efres Belmonte-Reche
NANorma Adán
Norma Adán
MCMarta Caro
Marta Caro
MMMaría Luisa Mateos-Martín
María Luisa Mateos-Martín
JMJuan Carlos Morales
Juan Carlos Morales

1 May 2016 in EBioMedicine
Verified
Journal Article
Open access
RGRodrigo Meléndez García
Rodrigo Meléndez García
DZDavid Arredondo Zamarripa
David Arredondo Zamarripa
EAEdith Arnold
Edith Arnold
XRXarubet Ruiz-Herrera
Xarubet Ruiz-Herrera
RIRamsés Noguez Imm
Ramsés Noguez Imm
STStéphanie Thebault
Stéphanie Thebault
The identification of pathways necessary for retinal pigment epithelium (RPE) function is fundamental to uncover therapies for blindness. Prolactin (PRL) receptors are expressed in the retina, but nothing is known about the role of PRL in RPE. Using the adult RPE 19 (ARPE-19) human cell line and mouse RPE, we identified the presence of PRL receptors and demonstrated that PRL is necessary for RPE cell survival via anti-apoptotic and antioxidant actions. PRL promotes the antioxidant capacity of ARPE-19 cells by reducing glutathione. It also blocks the hydrogen peroxide-induced increase in deacetylase sirtuin 2 (SIRT2) expression, which inhibits the TRPM2-mediated intracellular Ca(2+) rise associated with reduced survival under oxidant conditions. RPE from PRL receptor-null (prlr(-/-)) mice showed increased levels of oxidative stress, Sirt2 expression and apoptosis, effects that were exacerbated in animals with advancing age. These observations identify PRL as a regulator of RPE homeostasis.

1 June 2014 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
MZMiriam Zamorano
Miriam Zamorano
MLMaria G. Ledesma-Colunga
Maria G. Ledesma-Colunga
NANorma Adán
Norma Adán
CVCamila Vera-Massieu
Camila Vera-Massieu
MLMaria Lemini
Maria Lemini
CCCarmen Clapp
Carmen Clapp

29 January 2014 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
EAEdith Arnold
Edith Arnold
STStéphanie Thebault
Stéphanie Thebault
GBGerman Baeza-Cruz
German Baeza-Cruz
DZDavid Arredondo Zamarripa
David Arredondo Zamarripa
NANorma Adán
Norma Adán
CCCarmen Clapp
Carmen Clapp
Retinal degeneration is characterized by the progressive destruction of retinal cells, causing the deterioration and eventual loss of vision. We explored whether the hormone prolactin provides trophic support to retinal cells, thus protecting the retina from degenerative pressure. Inducing hyperprolactinemia limited photoreceptor apoptosis, gliosis, and changes in neurotrophin expression, and it preserved the photoresponse in the phototoxicity model of retinal degeneration, in which continuous exposure of rats to bright light leads to retinal cell death and retinal dysfunction. In this model, the expression levels of prolactin receptors in the retina were upregulated. Moreover, retinas from prolactin receptor-deficient mice exhibited photoresponsive dysfunction and gliosis that correlated with decreased levels of retinal bFGF, GDNF, and BDNF. Collectively, these data unveiled prolactin as a retinal trophic factor that may regulate glial–neuronal cell interactions and is a potential therapeutic molecule against retinal degeneration.

15 May 2017 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
MLMaria G. Ledesma-Colunga
Maria G. Ledesma-Colunga
NANorma Adán
Norma Adán
GOGeorgina Ortiz
Georgina Ortiz
MSMariana Solís-Gutiérrez
Mariana Solís-Gutiérrez
FLFernando López-Barrera
Fernando López-Barrera
CCCarmen Clapp
Carmen Clapp
Prolactin (PRL) reduces joint inflammation, pannus formation, and bone destruction in rats with polyarticular adjuvant-induced arthritis (AIA). Here, we investigate the mechanism of PRL protection against bone loss in AIA and in monoarticular AIA (MAIA). Joint inflammation, trabecular bone loss, and osteoclastogenesis were evaluated in rats with AIA treated with PRL (via osmotic minipumps) and in mice with MAIA that were null (Prlr-/-) or not (Prlr+/+) for the PRL receptor. To help define target cells, synovial fibroblasts from Prlr+/+ mice were treated or not with proinflammatory cytokines ((Cyt), including TNFα, IL-1β, and interferon (IFN)γ) with or without PRL, and these synovial cells were co-cultured or not with bone marrow osteoclast progenitors from Prlr+/+ or Prlr-/- mice. In AIA, PRL treatment reduced joint swelling, increased trabecular bone area, lowered osteoclast density, and reduced mRNA levels of osteoclast-associated genes (tartrate-resistant acid phosphatase (Trap)), cathepsin K (Ctsk), matrix metalloproteinase 9 (Mmp9), and receptor activator of nuclear factor κB or RANK (Tnfrsf11a)), of genes encoding cytokines with osteoclastogenic activity (Tnfa, Il1b, Il6, and receptor activator of nuclear factor κB ligand or RANKL (Tnfrsf11)), and of genes encoding for transcription factors and cytokines related to T helper (Th)17 cells (Rora, Rorc, Il17a, Il21, Il22) and to regulatory T cells (Foxp3, Ebi3, Il12a, Tgfb1, Il10). Prlr-/- mice with MAIA showed enhanced joint swelling, reduced trabecular bone area, increased osteoclast density, and elevated expression of Tnfa, Il1b, Il6, Trap, Tnfrsf11a, Tnfrsf11, Il17a, Il21, Il22, 1 l23, Foxp3, and Il10. The expression of the long PRL receptor form increased in arthritic joints, and in synovial membranes and cultured synovial fibroblasts treated with Cyt. PRL induced the phosphorylation/activation of signal transducer and activator of transcription-3 (STAT3) and inhibited the Cyt-induced expression of Il1b, Il6, and Tnfrsf11 in synovial fibroblast cultures. The STAT3 inhibitor S31-201 blocked inhibition of Tnfrsf11 by PRL. Finally, PRL acted on both synovial fibroblasts and osteoclast precursor cells to downregulate Cyt-induced osteoclast differentiation. PRL protects against osteoclastogenesis and bone loss in inflammatory arthritis by inhibiting cytokine-induced expression of RANKL in joints and synovial fibroblasts via its canonical STAT3 signaling pathway.